Israeli Start-up preparing for a post-antibiotics world – BiomX is planning future treatments for Crohn’s Disease, colitis, and even cancer | Jerusalem Post
Israeli startup BiomX, which is developing a treatment that selectively kills specific bacteria, last week completed a $24 million financing round. The company was founded in 2015 on the basis of research by two Weizmann Institute scientists: Dr. Eran Elinav, a specialist in microbiome – the mix of bacteria in the human body (he is also known from DayTwo, which developed an app for nutritional consultation according to a person’s individual composition of bacteria), and Professor Rotem Sorek, an expert in genetic engineering and bacterial genetics. The third founder is MIT Professor Timothy K. Lu, who specializes in genetic engineering of anti-bacterial viruses.
Hinterlasse eine Antwort
Sie müssen... (sein)angemeldet sein um einen Kommentar zu schreiben.